Review

Hepatic Steatosis in Type 1 Diabetes

Simon E. Regnell, Ake Lernmark

Manuscript submitted January 7, 2012; resubmitted January 20, 2012; accepted February 5, 2012.

Keywords: type 1 diabetes, hepatic steatosis, non-alcoholic fatty liver disease, NAFLD, hepatic fat, glycogen synthesis, insulin, hepatocyte

Abstract

Islet autoimmunity in type 1 diabetes results in the loss of the pancreatic β-cells. The consequences of insulin deficiency in the portal vein for liver fat are poorly understood. Under normal conditions, the portal vein provides 75% of the liver blood supply. Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) may be more common in type 1 diabetes than previously thought, and may serve as an independent risk marker for some chronic diabetic complications. The pathogenesis of NAFLD remains obscure, but it has been hypothesized that hepatic fat accumulation in type 1 diabetes may be due to lipoprotein abnormalities, hyperglycemia-induced activation of the transcription factors carbohydrate response element-binding protein (ChREBP) and sterol regulatory element-binding protein 1c (SREBP-1c), upregulation of glucose transporter 2 (GLUT2) with subsequent intrahepatic fat synthesis, or a combination of these mechanisms. Novel approaches to non-invasive determinations of liver fat may clarify the consequences for liver metabolism when the pancreas has ceased producing insulin. This article aims to review the factors potentially contributing to hepatic steatosis in type 1 diabetes, and to assess the feasibility of using liver fat as a prognostic and/or diagnostic marker for the disease. It provides a background and a case for possible future studies in the field.

Fulltext: HTML , PDF (228KB)

This article has been cited by other articles:

	Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis Yoshimine Y, Uto H, Kumagai K, Mawatari S, Arima S, Ibusuki R, Mera K, Nosaki T, Kanmura S, Numata M, Tamai T, Moriuchi A, Tsubouchi H, Ido A Oncol Rep 2015. 33(4):1657-1666
	Effect of exercise training on liver antioxidant enzymes in STZ-diabetic rats Lima TI, Monteiro IC, Valença S, Leal-Cardoso JH, Fortunato RS, Carvalho DP, Teodoro BG, Ceccatto VM Life Sci 2015. pii:S0024-3205(15)00100-9
	Alloxan-Induced Diabetes Causes Morphological and Ultrastructural Changes in Rat Liver that Resemble the Natural History of Chronic Fatty Liver Disease in Humans Lucchesi AN, Cassettari LL, Spadella CT J Diabetes Res 2015. 2015:494578
	Clinical profile of nonalcoholic fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Mohan V Endocr Pract 2014. 20(12):1249-1257
	Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M J Pharm Pharmacol 2014. 66(7):975-987
	Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes Harman DJ, Kaye PV, Harris R, Suzuki A, Gazis A, Aithal GP Hepatology 2014. 60(1):158-168
	Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes Sahini N, Borlak J Prog Lipid Res 2014. 54:86-112
	Passive fructose transporters in disease: a molecular overview of their structural specificity McQuade DT, Plutschack MB, Seeberger PH Org Biomol Chem 2013. 11(30):4909-4920
	Glycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders Rajas F, Labrune P, Mithieux G Diabetes Metab 2013. 39(5):377-387
	Cannabinoid 1 receptor in fatty liver Regnell SE Hepatol Res 2013. 43(2):131-138
	Non-alcoholic fatty liver disease in common endocrine disorders Hazlehurst JM, Tomlinson JW Eur J Endocrinol 2013. 169(2):R27-R37
	The role of fructose transporters in diseases linked to excessive fructose intake Douard V, Ferraris RP J Physiol 2013. 591(Pt 2):401-414
	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals Masuoka HC, Chalasani N Ann N Y Acad Sci 2013. 1281:106-122
	Flow synthesis of a versatile fructosamine mimic and quenching studies of a fructose transport probe Plutschack MB, McQuade DT, Valenti G, Seeberger PH Beilstein J Org Chem 2013. 9:2022-2027